Celgene Corp. to pay $280M to settle cancer drug fraud suit

Celgene Corp. to pay $280M to settle cancer drug fraud suit


A New Jersey pharmaceutical company has agreed to pay $280 million to settle a federal lawsuit alleging it committed fraud promoting two cancer drugs for unapproved purposes.



from Biotech News